After failed SPAC and phase 3 fumble, Amicus gene therapy hits another delay to approvalnews2022-05-11T13:43:20+00:00May 11th, 2022|FierceBiotech|
After phase 3 fumble and failed SPAC, Amicus’ Pompe disease drug hits another delay to approvalnews2022-05-11T13:43:20+00:00May 11th, 2022|FierceBiotech|
Inovio CEO departs, leaving Jacqueline Shea in charge of ‘particularly challenging period’ in the DNA vaccine biotech’s historynews2022-05-11T13:30:24+00:00May 11th, 2022|FierceBiotech|
Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapiesnews2022-05-11T11:47:10+00:00May 11th, 2022|FierceBiotech|
Takeda scraps dream of getting rare disease drug to market in latest setback to Wave 1 pipelinenews2022-05-11T11:29:17+00:00May 11th, 2022|FierceBiotech|
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reelingnews2022-05-11T07:33:53+00:00May 11th, 2022|FierceBiotech|
Can FDA replicate Operation Warp Speed for rare diseases? Not yet, but Peter Marks has some ideasnews2022-05-10T22:26:19+00:00May 10th, 2022|FierceBiotech|
Rallybio wades into Sanofi storeroom for $3M rare disease dealnews2022-05-10T16:33:14+00:00May 10th, 2022|FierceBiotech|
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new namenews2022-05-10T14:26:28+00:00May 10th, 2022|FierceBiotech|
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spraynews2022-05-10T13:25:01+00:00May 10th, 2022|FierceBiotech|
